# A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

> **NCT04826341** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- HRD Cancer
- SCLC
- Advanced Solid Tumors

## Interventions

- **DRUG:** Berzosertib
- **DRUG:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT04826341
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-20
- **Primary completion:** 2028-03-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826341, "A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04826341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*